The expression of E-cadherin was higher in patients with pSCC (58.3%) compared to those with pADC (29.7%) in NSCLC cohort (Supplementary Table 1) and the H-score of E-cadherin was higher in patients with pSCC (mean, 92.8) than in those with pADC (mean, 52.1) among NSCLC cohort. The gene discussed is CDH1; the disease is non-small cell lung carcinoma.